Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $55.4444.RAPT has been the subject of a number of recent analyst reports. Wells Fargo & Company set a $72.00 price objective on Rapt Therapeutics and gave the stock an "overweight" rating in a research report on Monday, November 3rd. Leerink Partnrs upgraded Rapt Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 25th. JPMorgan Chase & Co. boosted their price objective on Rapt Therapeutics from $55.00 to $57.00 and gave the company an "overweight" rating in a research report on Wednesday, November 12th. Cowen initiated coverage on shares of Rapt Therapeutics in a research report on Thursday, December 18th. They set a "buy" rating for the company. Finally, Piper Sandler started coverage on shares of Rapt Therapeutics in a research report on Friday. They set an "overweight" rating and a $95.00 price target on the stock.Get Rapt Therapeutics alerts:View Our Latest Stock Analysis on RAPTInstitutional Trading of Rapt TherapeuticsA number of hedge funds and other institutional investors have recently modified their holdings of RAPT. Velan Capital Investment Management LP acquired a new position in Rapt Therapeutics in the third quarter valued at about $2,063,000. Susquehanna International Group LLP increased its position in shares of Rapt Therapeutics by 173.4% during the third quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock valued at $1,170,000 after acquiring an additional 28,782 shares during the last quarter. Millennium Management LLC raised its stake in shares of Rapt Therapeutics by 75.2% in the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company's stock valued at $1,013,000 after acquiring an additional 16,854 shares during the period. Boone Capital Management LLC acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $20,180,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $1,326,000. 99.09% of the stock is owned by institutional investors and hedge funds. Rapt Therapeutics Stock PerformanceShares of NASDAQ:RAPT opened at $34.06 on Wednesday. The stock's 50-day simple moving average is $32.31 and its two-hundred day simple moving average is $22.63. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $42.39. The stock has a market capitalization of $943.80 million, a price-to-earnings ratio of -3.08 and a beta of 0.45. Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.23. As a group, equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year. About Rapt Therapeutics (Get Free Report)RAPT Therapeutics, Inc NASDAQ: RAPT is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies. The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.Featured StoriesFive stocks we like better than Rapt Therapeutics“Ominous day” coming to stocks…Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyPunch these codes into your ordinary brokerage accountThe Crash Has Already Started (Most Just Don’t See It Yet)Trump just signed itThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Rapt Therapeutics Right Now?Before you consider Rapt Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here